ArticleHuman vaccines & immunotherapeutics2024
Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody.
Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.Human vaccines & immunotherapeutics · 2026Pooled it
- 5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Assessing the willingness and preference of pregnant and postpartum women regarding RSV immunization for newborns in western China: A mixed-methods study.Human vaccines & immunotherapeutics · 2026Article
- Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada.Human vaccines & immunotherapeutics · 2026Article
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- RSV Prophylaxis in Neonates: Implementation and Parental Acceptance during the First RSV Season in Germany.Geburtshilfe und Frauenheilkunde · 2026Article
- Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study.Pediatric pulmonology · 2026Article
- Ultrasound Procedure Codes Enable Timely Surveillance of Ongoing Pregnancies: A Nationwide Population-Based Register Study.Pharmacoepidemiology and drug safety · 2026Article
- Preferences of Dutch Parents and Expectant Parents for Respiratory Syncytial Virus Prevention Strategies: A Discrete Choice Experiment.Infectious diseases and therapy · 2025Article
- Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.Open forum infectious diseases · 2025Review
- Article
- Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review.Vaccines · 2025Review
- Knowledge About Respiratory Syncytial Virus and Acceptance of Infant Monoclonal Antibody for RSV and RSV Vaccination During Pregnancy.The Pediatric infectious disease journal · 2025Article
- Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France.EClinicalMedicine · 2025Article
- Epidemiologic characteristics of immunoglobulin M antibodies in lower respiratory tract infection pathogens of children: association with severe pneumonia in Chengdu city from 2019 to 2023.American journal of translational research · 2025Article
- Correlation analysis between the severity of respiratory syncytial virus pneumonia and the expression levels of inflammatory cytokines in bronchoalveolar lavage fluid among infants and young children.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory Syncytial Virus poses a significant global public health threat, particularly affecting infants aged less than one year of age. Recently, two forms of passive immunization against infant RSV have been developed and brought to market; nirsevimab a long-acting monoclonal antibody (mAb) and RSV-PreF, a maternal RSV vaccine. The acceptability and uptake of these products will play a pivotal role in determining the success of any national immunization strategy aimed at safeguarding infants from RSV. It is crucial at this time to reflect on the factors that influence parental decisions surrounding immunization to facilitate more informed discussions, enhance healthcare communication, and contribute to the design of effective RSV prevention strategies that resonate with the concerns and aspirations of parents worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.